Methods and devices for treating pruritus associated with chronic kidney disease

Transmucosal administration of nalmefene via a self-supporting mucosal adhesive film addresses the ineffectiveness of current treatments for chronic kidney disease-related itching by directly reducing substance P levels, offering effective relief for pruritus through buccal or sublingual delivery.

JP2026110601APending Publication Date: 2026-07-02AVIOR BIO INC
0 Cites 0 Cited by

Patent Information

Application Number
JP2026061594
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-10-18
Filing Date
2026-04-03
Publication Date
2026-07-02

AI Technical Summary

Technical Problem

Current treatments for pruritus associated with chronic kidney disease, cholestatic pruritus, and nodular prurigo are ineffective, particularly for moderate to severe cases, and there are no approved products in the United States for these conditions.

Method used

Transmucosal administration of nalmefene or its pharmaceutically acceptable salts, specifically through buccal or sublingual routes, using a single-layer self-supporting mucosal adhesive film with distinct domains for improved delivery and absorption.

Benefits of technology

Effectively reduces the level of substance P, providing relief from chronic renal disease-associated pruritus, cholestatic pruritus, and nodular prurigo by delivering nalmefene directly into the bloodstream, bypassing first-pass metabolism and improving bioavailability.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

To provide a method and device for treating pruritus associated with chronic kidney disease. [Solution] The subject matter of this disclosure relates to an effective method for treating pruritus associated with chronic kidney disease. Specifically, the method comprises administering nalmefene transmucosally to treat pruritus associated with chronic kidney disease, as well as cholestatic pruritus and / or nodular prurigo. The nalmefene is disposed on a monolayer film comprising at least two distinct domains. The film may contain a first distinct domain comprising about 50–100 weight percent of a polymer matrix, and the second distinct domain may contain nalmefene or a pharmaceutically acceptable nalmefene salt.
Need to check novelty before this filing date? Find Prior Art